Orchid Pharma Limited · NSE:ORCHPHARMA
Orchid Pharma — Q3 FY2026 Earnings Presentation
8 slides from Orchid Pharma's earnings presentation, Feb 11, 2026
Slide 1: Investors Presentation - Quarter III ended December 31, 2025 (exchange cover letter)
February 11, 2026 National Stock Exchange of India Limited, BSE Limited Exchange Plaza, Bandra Kurla Complex Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai-400051 Dalal Street, Fort, Mumbai-400001 Symbol: ORCHPHARMA Scrip Code: 524372 Ref: (i) Regulation 30 of Securities and Exchange Board of India (
Slide 2: Financials Q3 & 9M FY-26
Orchid Pharma Limited Financials Q3 & 9M FY-26 • All results in standalone basis. • These are approx. figures, for exact nos. please refer financials for details
Slide 3: Financial Performance
Financial Performance (Amt. in Cr.) Q3-26 Q3-25 Change % 9M-26 9M-25 % Change Sales 207 217 -5% 574 684 -16% Other Income 11 10 +10% 42 26 +62% COGS 143 124 374 406 Employee Exp 23 22 +5% 69 64 +8% Other Exp 38 44 -14% 114 125 -9% EBITDA* 13 37 -65% 58 115 -50% % to Sales 6% 17% 10% 17% Interest 3 4
Slide 4: Turnover (Amt. in Cr.)
Turnover (Amt. in Cr.) 250 221 217 207 200 159 160 150 100 50 - Q3-22 Q3-23 Q3-24 Q3-25 Q3-26
Slide 5: EBITDA & PBT as % to Sales Q3
EBIDTA & PBT as % to Sales Q3 25% EBIDTA PBT 20% 19% 17% 15% 14% 14% 11% 11% 10% 6% 5% 4% -3% 0% Q3 - 22 Q3 - 23 Q3 - 24 Q3 - 25 Q3 - 26 -5% -6% -10%
Slide 6: P&L Analysis – Gross Margin % to Sales Q3
P&L Analysis – Gross Margin % to Sales Q3 50% 45% 45% 43% 41% 40% 40% 35% 31% 30% 25% 20% 15% 10% 5% 0% Q3-22 Q3-23 Q3-24 Q3-25 Q3-26
Slide 7: P&L Analysis – Exp. % to Sales Q3
P&L Analysis – Exp. % to Sales Q3 Emp Benefit Other Exp 25% 22% 21% 20% 20% 20% 18% 15% 10% 10% 11% 10% 10% 9% 5% 0% Q3-22 Q3-23 Q3-24 Q3-25 Q3-26
Slide 8: Thank You
Thank You